Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.

Combining explainable machine learning, demographic and multi-omic data to inform precision medicine strategies for inflammatory bowel disease

Open access

Published version of a preprint

Abstract

Inflammatory bowel diseases (IBDs), including ulcerative colitis and Crohn’s disease, affect several million individuals worldwide. These diseases are heterogeneous at the clinical, immunological and genetic levels and result from complex host and environmental interactions. Investigating drug efficacy for IBD can improve our understanding of why treatment response can vary between patients. We propose an explainable machine learning (ML) approach that combines bioinformatics and domain insight, to integrate multi-modal data and predict inter-patient variation in drug response. Using explanation of our models, we interpret the ML models’ predictions to infer unique combinations of important features associated with pharmacological responses obtained during preclinical testing of drug candidates in ex vivo patient-derived fresh tissues. Our inferred multi-modal features that are predictive of drug efficacy include multi-omic data (genomic and transcriptomic), demographic, medicinal and pharmacological data. Our aim is to understand variation in patient responses before a drug candidate moves forward to clinical trials. As a pharmacological measure of drug efficacy, we measured the reduction in the release of the inflammatory cytokine TNFα from the fresh IBD tissues in the presence/absence of test drugs. We initially explored the effects of a mitogen-activated protein kinase (MAPK) inhibitor; however, we later showed our approach can be applied to other targets, test drugs or mechanisms of interest. Our best model predicted TNFα levels from demographic, medicinal and genomic features with an error of only 4.98% on unseen patients. We incorporated transcriptomic data to validate insights from genomic features. Our results showed variations in drug effectiveness (measured by ex vivo assays) between patients that differed in gender, age or condition and linked new genetic polymorphisms to patient response variation to the anti-inflammatory treatment BIRB796 (Doramapimod). Our approach models IBD drug response while also identifying its most predictive features as part of a transparent ML precision medicine strategy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0263248

Cites

55 of 55 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig 1 Schematic representation of the study. Detailing (to the left) the steps undertaken to generate datasets, process these datasets, build and train ML models to make predictions and the interpretation of those predictions. Detailing (to the right) the different approaches, in order of usage where possible, which we used for dimensionality reduction of the medicinal, demographic, genomic and transcriptomic feature sets that were used to train our models and provide explanations for the predictions. Ultimately models were trained to predict the TNFα level or inflammatory response after compound treatment of fresh tissues.
Fig 1 Schematic representation of the study. Detailing (to the left) the steps undertaken to generate datasets, process these datasets, build and train ML models to make predictions and the interpretation of those predictions. Detailing (to the right) the different approaches, in order of usage where possible, which we used for dimensionality reduction of the medicinal, demographic, genomic and transcriptomic feature sets that were used to train our models and provide explanations for the predictions. Ultimately models were trained to predict the TNFα level or inflammatory response after compound treatment of fresh tissues.CC BY · PubMed Central
Fig 2 Spearman correlation of demographic information with TNFα response per drug. To compute the Spearman correlation for binary features we used the following encoding; condition Crohn’s/ulcerative colitis = 0/1, gender female/male = 0/1, resection area colon/ileum = 0/1. See section demographic feature preparation for ML in Methods for more details.
Fig 2 Spearman correlation of demographic information with TNFα response per drug. To compute the Spearman correlation for binary features we used the following encoding; condition Crohn’s/ulcerative colitis = 0/1, gender female/male = 0/1, resection area colon/ileum = 0/1. See section demographic feature preparation for ML in Methods for more details.CC BY · PubMed Central
Fig 3 Comparison of ML model error rates for the prediction of BIRB796 (10nM) drug response for different combinations of demographic and medicinal features. Here we show box plots (left) of mean absolute error (MAE) values (as percentages) computed during 10-fold cross validation. The horizontal line in each boxplot is the median of the MAE over 10 folds, where each of the test folds has 3 randomly chosen patients. Note all target drug responses have been normalized on a scale of 0–1 and here we show percentages of MAE values. On the right we report median, average and standard deviation MAE as percentages for each ML method. We computed the predictive error for demographic features age, gender, condition plus (a) all 53 medicinal features or (b) only those medicinal features correlated to BIRB796 at |rs| > 0.3.
Fig 3 Comparison of ML model error rates for the prediction of BIRB796 (10nM) drug response for different combinations of demographic and medicinal features. Here we show box plots (left) of mean absolute error (MAE) values (as percentages) computed during 10-fold cross validation. The horizontal line in each boxplot is the median of the MAE over 10 folds, where each of the test folds has 3 randomly chosen patients. Note all target drug responses have been normalized on a scale of 0–1 and here we show percentages of MAE values. On the right we report median, average and standard deviation MAE as percentages for each ML method. We computed the predictive error for demographic features age, gender, condition plus (a) all 53 medicinal features or (b) only those medicinal features correlated to BIRB796 at |rs| > 0.3.CC BY · PubMed Central
Fig 4 Comparison of ML model error rates for the prediction of BIRB796 (10nM) drug response for different combinations of demographic, medicinal and genomic features. Here we show box plots (left) of mean absolute error values (as percentages) computed during 10-fold cross validation. The horizontal line in each boxplot is the median of the MAE over 10 folds, where each of the test folds has 3 randomly chosen patients. Note that all target drug responses have been normalized on a scale of 0–1 and here we show percentages of MAE values. On the right, we report median, average and standard deviation MAE as percentages for each ML method. We computed the predictive error using demographic features age, gender and condition and correlated medicinal features plus (a) all SNPs (33,577) or (b) the 71 curated known and associated SNPs.
Fig 4 Comparison of ML model error rates for the prediction of BIRB796 (10nM) drug response for different combinations of demographic, medicinal and genomic features. Here we show box plots (left) of mean absolute error values (as percentages) computed during 10-fold cross validation. The horizontal line in each boxplot is the median of the MAE over 10 folds, where each of the test folds has 3 randomly chosen patients. Note that all target drug responses have been normalized on a scale of 0–1 and here we show percentages of MAE values. On the right, we report median, average and standard deviation MAE as percentages for each ML method. We computed the predictive error using demographic features age, gender and condition and correlated medicinal features plus (a) all SNPs (33,577) or (b) the 71 curated known and associated SNPs.CC BY · PubMed Central
Fig 5 Comparison of ML model explanations for the prediction of BIRB796 (10nM) drug response for demographic, medicinal and genomic features. Here we show SHAP plots that contain explanations for the predictions generated by our best model, KNN, using (a, c) our best “demographic+medicinal” feature set and (b, d) our best “demographic+medicinal+SNP” feature set. The SHAP bar plots (a, b) show the top 20 features ranked by their impact on the model prediction. The SHAP dot plot (c, d) shows the same top 20 ranked features together with the weight of each feature (row) for the prediction of TNFα level for each donor (a donor is a blue or red dot). The figure legend (top right) details the colour and corresponding value that each feature has for each donor (coloured dot). For example, donors that are older are red dots in the plot, while younger donors are blue dots. Similarly, donors that have a SNP allele are shown as red dots, while donors with the reference allele are represented as blue dots.
Fig 5 Comparison of ML model explanations for the prediction of BIRB796 (10nM) drug response for demographic, medicinal and genomic features. Here we show SHAP plots that contain explanations for the predictions generated by our best model, KNN, using (a, c) our best “demographic+medicinal” feature set and (b, d) our best “demographic+medicinal+SNP” feature set. The SHAP bar plots (a, b) show the top 20 features ranked by their impact on the model prediction. The SHAP dot plot (c, d) shows the same top 20 ranked features together with the weight of each feature (row) for the prediction of TNFα level for each donor (a donor is a blue or red dot). The figure legend (top right) details the colour and corresponding value that each feature has for each donor (coloured dot). For example, donors that are older are red dots in the plot, while younger donors are blue dots. Similarly, donors that have a SNP allele are shown as red dots, while donors with the reference allele are represented as blue dots.CC BY · PubMed Central
Fig 6 Comparison of ML model explanations for the prediction of response to three drugs (x2 doses) for demographic, medicinal and genomic features. Here we show SHAP plots that contain explanations for the predictions as generated by our best ML models (as defined in the table to the right) using “demographic+medicinal+SNP” features as appropriate per drug for (a) BIRB796 100nM (b) Pred 1uM (c) Pred 100 nM (d) 5-ASA. Plots (a-d) show the top 20 ranked features together with the weight of each feature (row) for the prediction of TNFα level for each donor (a donor is a blue or red dot). Figure legend details the colour and corresponding value that each feature has for each donor (coloured dot). The table to the right shows, for each drug, the best ML model and the median, average and standard deviation mean absolute error values (MAEs) computed during 10-fold cross validation. Note all target drug responses have been normalized on a scale of 0–1 and here we show percentages of MAE values.
Fig 6 Comparison of ML model explanations for the prediction of response to three drugs (x2 doses) for demographic, medicinal and genomic features. Here we show SHAP plots that contain explanations for the predictions as generated by our best ML models (as defined in the table to the right) using “demographic+medicinal+SNP” features as appropriate per drug for (a) BIRB796 100nM (b) Pred 1uM (c) Pred 100 nM (d) 5-ASA. Plots (a-d) show the top 20 ranked features together with the weight of each feature (row) for the prediction of TNFα level for each donor (a donor is a blue or red dot). Figure legend details the colour and corresponding value that each feature has for each donor (coloured dot). The table to the right shows, for each drug, the best ML model and the median, average and standard deviation mean absolute error values (MAEs) computed during 10-fold cross validation. Note all target drug responses have been normalized on a scale of 0–1 and here we show percentages of MAE values.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 53 references

Research works printed but not linked: 1

  1. S.M. Carlton, 2013, Encyclopedia of Pain

Cited by

See all 38

Metadata

Authors
Gardiner, L.-J., Carrieri, A. P., Bingham, K., Macluskie, G., Bunton, D., McNeil, M., & Pyzer-Knapp, E. O.
Affiliations
  • Sci-Tech Daresbury (GB)
  • ReproCELL (United Kingdom) (GB)
  • Queen Elizabeth University Hospital (GB)
Corresponding author
  • Gardiner, Laura-Jayne
  • Carrieri, Anna Paola
Venue
PLOS ONE
Published
2022-02-23
Volume
17
Issue
2
Pages
e0263248
ISSN
1932-6203 (ISSN-L)
OpenAlex
W4213237113
Cited by
36
References
53
Citations by year
2026: 7 · 2025: 10 · 2024: 7 · 2023: 9 · 2022: 2
FWCI
4.22
Type
journal article
Language
en
Open access
Locations
  • PLoS ONE (publishedVersion, cc-by)
  • medRxiv (acceptedVersion, cc-by-nd)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Science and Technology Facilities Council (submittedVersion, cc-by)
Funders
  • UK Research and Innovation (Hartree National Centre for Digital Innovation)
  • Scottish Funding Council (Precision Medicine Scotland Innovation Centre (PMS-IC))
Topics
  • Health Sciences › Medicine › Gastroenterology › Inflammatory Bowel Disease
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
Keywords
inflammatory bowel disease, Crohn's disease, ulcerative colitis, precision medicine, explainable machine learning, drug response prediction, interpatient variability, multi-omics integration, MAPK inhibitors, genetic polymorphism, transcriptomics, demographic predictors, precision dosing
MeSH terms
Machine Learning, Adolescent, Adult, Aged, Anti-Inflammatory Agents, Non-Steroidal, Colitis, Ulcerative, Crohn Disease, Drug Evaluation, Preclinical, Female, Humans, Male, Middle Aged, Naphthalenes, Phenylurea Compounds, Prednisolone, Pyrazoles, Tumor Necrosis Factor-alpha, Signal Transduction, Mesalamine, Genomics, Young Adult, Precision Medicine, Transcriptome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Combining explainable machine learning, demographic and multi-omic data to inform precision medicine strategies for inflammatory bowel disease. https://app.cochat.ai/papers/10.1371/journal.pone.0263248
The paper
Gardiner, L.-J., Carrieri, A. P., Bingham, K., Macluskie, G., Bunton, D., McNeil, M., & Pyzer-Knapp, E. O. (2022). Combining explainable machine learning, demographic and multi-omic data to inform precision medicine strategies for inflammatory bowel disease. PLOS ONE. https://doi.org/10.1371/journal.pone.0263248

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.